- Notoginsenoside Ft1
-
- $15.00/ kg
-
2024-04-22
- CAS:155683-00-4
- Min. Order: 1kg
- Purity: 99.912%
- Supply Ability: 10ton
- Notoginsenoside Ft1
-
- $0.00 / 25KG
-
2023-07-01
- CAS:155683-00-4
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 50000KG/month
- Notoginsenoside Ft1
-
- $0.00 / 20mg
-
2023-02-24
- CAS:155683-00-4
- Min. Order: 5mg
- Purity: ≥98%(HPLC)
- Supply Ability: 10 g
|
| | Notoginsenoside Ft1 Basic information |
| Product Name: | Notoginsenoside Ft1 | | Synonyms: | Notoginsenoside Ft1;(3beta,12beta,20R)-12,20-Dihydroxydammar-24-en-3-yl O-beta-D-xylopyranosyl-(1- 2)-O-beta-D-glucopyranosyl-(1-2)-beta-D-glucopyranoside;product/153944;β-D-Glucopyranoside, (3β,12β,20R)-12,20-dihydroxydammar-24-en-3-yl O-β-D-xylopyranosyl-(1→2)-O-β-D-glucopyranosyl-(1→2)-;(2S,3R,4S,5R)-2-[(2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5S,6R)-4,5-dihydroxy-2-[[(3S,5R,8R,9R,10R,12R,13R,14R,17S)-12-hydroxy-17-[(2R)-2-hydroxy-6-methylhept-5-en-2-yl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-6-(hydroxymethyl)oxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol | | CAS: | 155683-00-4 | | MF: | C47H80O17 | | MW: | 917.13 | | EINECS: | | | Product Categories: | chemical reagent;pharmaceutical intermediate;phytochemical;reference standards from Chinese medicinal herbs (TCM).;standardized herbal extract | | Mol File: | 155683-00-4.mol |  |
| | Notoginsenoside Ft1 Chemical Properties |
| Boiling point | 997.8±65.0 °C(Predicted) | | density | 1.36±0.1 g/cm3(Predicted) | | solubility | DMF: 20 mg/ml; DMF:PBS(pH 7.2)(1:1): 0.5 mg/ml; DMSO: 15 mg/ml; Ethanol: 5 mg/ml | | form | A crystalline solid | | pka | 12.84±0.70(Predicted) | | color | White to off-white |
| | Notoginsenoside Ft1 Usage And Synthesis |
| Description | Notoginsenoside Ft1 is a saponin originally isolated from P. notoginseng with diverse biological activities. It induces proliferation, migration, and tube formation of human umbilical vein endothelial cells (HUVECs) via nuclear translocation of hypoxia-inducible factor-1α (HIF-1α) and activation of the PI3K/AKT and Raf/MEK/ERK signaling pathways in a manner dependent on mammalian target of rapamycin (mTOR). Notoginsenoside Ft1 (45 μM) induces cell cycle arrest at the S and G2/M phases and promotes apoptosis of SH-SY5Y cells. It increases cGMP levels and induces relaxation of isolated precontracted rat mesenteric arteries, effects that are reversed by the nitric oxide synthase inhibitor L-NAME and ODQ , an inhibitor of soluble guanylyl cyclase. In vivo, notoginsenoside Ft1 (0.25, 2.5, and 25 mg/kg) promotes angiogenesis and decreases wound diameter in a mouse model of punched-hole ear injury. Notoginsenoside Ft1 (1.25 mg/kg) decreases tail bleeding time and increases thrombus weight in a rat tail bleeding assay. Topical administration of notoginsenoside Ft1 increases mRNA expression of the collagen expression, fibroblast proliferation, and scar formation genes COL1A1, COL3A1, TGF-β1, TGF-β3, and fibronectin, promotes neovascularization, reduces monocyte infiltration, and shortens wound closure time in a db/db mouse model of diabetic foot ulcers. |
| | Notoginsenoside Ft1 Preparation Products And Raw materials |
|